TP53 and hepatocellular carcinoma: In addition, EVs containing miR-25 released from HCC cells inhibited p53 expression in surrounding HCC cells, thereby restoring FOXM1 (a key regulator of cell cycle progression) expression, activating the HGF/Ras pathway, reversing the expression of sorafenib-induced apoptotic markers BCL2 and BAX, making HCC cells resistant to sorafenib (138).